论文部分内容阅读
阿司匹林、阿司匹林+氯吡格雷、血管紧张素转换酶抑制剂(ACEI)、血管紧张素Ⅱ受体拮抗剂(ARB)、β受体阻滞剂、他汀类药以及新型抗血小板药物和口服抗凝药的问世及应用,大大降低了心血管病患者的病死率,但是,目前心脑血管病仍是我国城乡居民的首位死因。增加高密度脂蛋白胆固醇和抗炎治疗是否有效、新型抗心力衰竭和抗心律失常药物的研发等问题尚有待解决;中国多年参与国际多中心临床试验的经验是否有助于提高我国临床试验及临床治疗水平;为此,《中国新药杂志》专访了中国工程院高润霖院士,请高院士就上述方面的最新进展进行了简明而权威的解读。
Aspirin, aspirin + clopidogrel, angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor antagonist (ARB), beta blockers, statins, novel antiplatelet agents and oral anticoagulation Advent and application of medicine, greatly reducing the mortality of patients with cardiovascular disease, however, the current cardiovascular and cerebrovascular disease is still the first cause of death of urban and rural residents. Increase the high-density lipoprotein cholesterol and anti-inflammatory treatment is effective, new anti-heart failure and anti-arrhythmic drug research and development and other issues remain to be resolved; China’s participation in international multi-center clinical trials for many years experience will help to improve our clinical trials and clinical To this end, “China New Drug Magazine” Interview with the Academy of Engineering, Academy of High Runlin, please academicians on the latest progress in these areas conducted a concise and authoritative interpretation.